A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)

The study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective treatment to prevent relapse in participants who have lymphoma DNA detected in their blood by an investigational test. For reference, CAR T cells are T cells (a type of immune system white blood cell) that have been engineered to attack cancer cells, like lymphoma.